A newly filed putative class action in the Northern District of California takes aim at supplement maker Pharmavite LLC, placing the company’s marketing and labeling practices under the microscope. In Spencer et al v. Pharmavite LLC, filed May 29, 2026, the named plaintiffs appear to be pursuing claims on behalf of consumers who purchased Pharmavite products allegedly marketed in a misleading manner.

While the complaint will provide the precise contours of the proposed class, cases like this typically define the class as purchasers of the challenged products during a specified limitations period, often on a statewide or nationwide basis depending on the claims asserted. In supplement litigation, plaintiffs frequently focus on front-label statements, health-related representations, ingredient descriptions, or “natural” and efficacy claims that allegedly influenced consumers’ purchasing decisions.

The defendant is Pharmavite LLC, a well-known player in the vitamin and dietary supplement market. That alone makes this case worth watching. Consumer class actions against major supplement manufacturers can carry significant exposure, particularly where plaintiffs seek certification of broad classes and damages or restitution tied to large-volume retail sales.

Although the docket entry does not by itself spell out every cause of action, these suits commonly assert California consumer protection claims such as violations of the Unfair Competition Law, False Advertising Law, and Consumers Legal Remedies Act, along with warranty, unjust enrichment, or common-law misrepresentation theories. The central issue is usually whether reasonable consumers were likely to be deceived by the product labeling and whether the alleged misstatements were material to purchase decisions.

The potential impact could be substantial. For consumer products companies, especially those in the heavily marketed wellness space, even a single labeling theory can create wide-ranging business risk: class certification battles, expert disputes over consumer perception and price premium models, and possible pressure to revise packaging or advertising. For plaintiffs’ counsel, supplement cases remain an active area because they often involve standardized labels and high-volume consumer sales—two features that can support class treatment if the theory is framed carefully.

Class action practitioners should keep an eye on this case for several reasons. First, it adds to the steady stream of food, beverage, and supplement labeling litigation in California federal courts. Second, any motion practice on standing, preemption, primary jurisdiction, or class certification could offer useful guidance for similar consumer cases. Third, Pharmavite’s market presence means the litigation may test how courts assess alleged deception in a sophisticated and crowded supplement marketplace.

View full case on Docket Alarm

A Massachusetts federal judge has allowed a multistate challenge against the federal government to continue, concluding at this early stage that the plaintiff states had already shown harm from the challenged federal actions. That ruling is important not because it resolves the merits, but because it clears one of the biggest threshold obstacles in public-law litigation: whether the states can establish a sufficiently concrete injury to stay in court.

According to the reporting, the U.S. Department of Justice will continue litigating the case in the U.S. District Court in Massachusetts after the judge determined the states had made the necessary showing of harm. In practical terms, that means the suit survives the government’s effort to halt it at the preliminary stage and will move forward into further merits litigation, motion practice, and potentially discovery.

For litigators, the ruling is a reminder that standing and irreparable harm remain central battlegrounds in challenges to federal policy. States frequently argue that federal action imposes downstream administrative, fiscal, or regulatory burdens on them, and judges continue to scrutinize whether those alleged injuries are immediate and measurable enough to support jurisdiction and preliminary relief. A finding that states have shown harm can shape the trajectory of the entire case, influencing settlement leverage, appellate strategy, and the timing of any nationwide or state-specific relief.

For in-house counsel and compliance teams, the decision matters because it preserves uncertainty around the underlying federal action being challenged. When a court allows a state-led suit to proceed, regulated entities may face a longer period in which enforcement expectations, compliance obligations, or implementation timelines remain unsettled. That is especially true where multiple states are aligned against the federal government, increasing the possibility of broader operational impact and coordinated follow-on actions.

The venue also matters. Massachusetts federal court has become a notable forum for high-stakes administrative and constitutional disputes involving federal policy, and early rulings there can have outsized practical consequences even before appellate review. A preliminary finding of harm does not guarantee the states will ultimately prevail, but it signals that the court sees the alleged injuries as serious enough to warrant continued judicial review.

Legal professionals should watch what comes next: whether DOJ seeks interlocutory review, how the court frames the merits questions, and whether the states pursue preliminary injunctive relief or expedited proceedings. In multistate enforcement and regulatory disputes, early standing rulings often provide the clearest indication of how aggressively a court may engage with the challenged federal conduct going forward.

The Patent Trial and Appeal Board’s June 2, 2026 public order in IPR2026-00252 is brief but still worth attention for PTAB practitioners: the Director denied discretionary review, leaving the underlying Board action in place. In practical terms, the decision reinforces how difficult it remains to obtain Director intervention absent a clear policy issue, legal error, or case-specific circumstance warranting extraordinary review.

Because this filing is a “Director Discretionary Decision: Deny,” the key takeaway is procedural rather than merits-driven. The Director did not reopen the panel’s work, did not modify the institution posture, and did not announce a new governing standard. That matters. In the post-Arthrex PTAB landscape, parties increasingly seek Director review as a strategic second look at institution-related rulings and other significant Board determinations. This order signals that such review remains selective and exceptional.

The legal reasoning, as reflected by the nature of the order, appears to be straightforward: the request did not justify discretionary intervention. Where the Director declines review without a substantive merits discussion, the denial generally should not be read as endorsement of every aspect of the panel’s reasoning. Instead, it usually indicates that the case does not present the kind of issue the Director believes warrants centralized correction, clarification, or policy guidance.

For practitioners, the lesson is familiar but important. A request for Director review must do more than argue that the panel got it wrong. The strongest requests identify a conflict with USPTO guidance, a recurring issue with broad systemic consequences, or an apparent departure from controlling law. Absent that, the odds of review are low. This is especially true where the request effectively seeks error correction on a fact-bound record rather than raising a question with institutional significance.

Just as important, this order does not appear to set new precedent or alter existing PTAB discretionary-denial doctrine. There is no indication of a precedential or informative designation, and no announced change to the standards governing institution, rehearing, or Director review. For that reason, its significance lies more in confirming current practice than in reshaping it.

Litigators handling parallel district court and PTAB proceedings should take note: Director review remains a limited tool, not a routine appellate layer. Parties should preserve their best arguments before the panel in the first instance and treat any Director-review request as a targeted policy submission, not merely a rehearing brief in different packaging.

View full case on Docket Alarm

The Eleventh Circuit’s May 28, 2026 opinion in No. 24-11688 is now available, but practitioners should note an immediate practical issue: the publicly available case details provided here do not include the substance of the court’s ruling, the claims at issue, or the panel’s reasoning. That means the key takeaway at this stage is less about the merits and more about workflow: when a new appellate decision drops, the first task is to identify whether it is precedential, unpublished, per curiam, jurisdictional, or merits-based, because each category has very different downstream consequences for briefing, removal strategy, settlement leverage, and issue preservation.

For lawyers tracking the Eleventh Circuit, those distinctions matter. A published opinion can alter the governing law across Alabama, Florida, and Georgia, particularly in recurring areas such as arbitration, standing, class certification, immunity, employment claims, and federal criminal procedure. An unpublished decision, while not binding in the same way, can still be highly useful for spotting how a panel is treating a procedural issue or how the court is applying existing precedent to a new factual pattern. And if the opinion addresses appellate jurisdiction, waiver, timeliness, or standards of review, it may have outsized significance for practitioners regardless of the underlying dispute.

From a litigation-management perspective, this is exactly the kind of filing attorneys should review quickly and in full. Appellate opinions often contain important guidance on preservation, harmless-error analysis, finality, and the framing of issues on appeal—topics that affect trial counsel and appellate counsel alike. Even where the court does not announce a new rule, it may clarify how strictly it expects litigants to preserve arguments, develop the record, or challenge lower-court reasoning. Those practical signals can influence motion practice and briefing strategy in pending cases.

If this opinion is published and breaks new ground, practitioners should assess whether it creates a circuit split, narrows or expands an existing doctrine, or changes the way district courts within the circuit are likely to handle similar issues. If instead it applies settled law to a specific record, the opinion may still be valuable as a roadmap for what arguments resonated—and what arguments failed.

Given the limited metadata currently available, the safest course is to pull the full decision, confirm its precedential status, and evaluate its effect on any active matters in the Eleventh Circuit. You can review the opinion here: View full case on Docket Alarm.

The U.S. Supreme Court has reaffirmed the Securities and Exchange Commission’s ability to seek disgorgement of ill-gotten gains in fraud cases, preserving a remedy that has long been central to the agency’s enforcement playbook. For securities litigators and compliance professionals, the ruling matters not just as a doctrinal win for the SEC, but as a practical confirmation that one of the agency’s strongest settlement and deterrence tools remains available.

Disgorgement allows the SEC to force defendants to give up profits allegedly obtained through unlawful conduct. In major fraud cases, that remedy can dramatically increase financial exposure beyond civil penalties and injunctive relief. By backing the SEC’s continued use of disgorgement in this context, the Court avoided a result that could have narrowed the agency’s leverage in investigations, settlement negotiations, and contested enforcement actions.

The decision is especially significant because the scope of SEC disgorgement authority has been under sustained scrutiny in recent years. Questions about whether disgorgement is equitable relief, a penalty, or something in between have shaped defenses in enforcement litigation and influenced how courts calculate recoverable amounts. The Supreme Court’s ruling gives the SEC firmer footing in fraud cases, even as disputes are likely to continue over issues such as net profits, tracing, joint-and-several liability, and whether funds must be returned to harmed investors.

For legal professionals, the immediate takeaway is that disgorgement remains a live and potent risk in SEC matters. Defense counsel will need to continue treating disgorgement exposure as a core part of early case assessment. In-house counsel and compliance teams should also view the ruling as a reminder that financial remedies in securities investigations can be substantial, particularly where the government alleges intentional misconduct or investor harm.

The ruling may also shape litigation strategy in lower courts. Parties watching the contours of SEC remedies can look to cases such as SEC v. Blackburn in the Fifth Circuit, where issues tied to SEC enforcement authority and available remedies have drawn close attention. For practitioners tracking how appellate courts apply Supreme Court guidance in enforcement disputes, that docket offers a useful point of comparison.

Bottom line: the SEC retains a critical enforcement mechanism in fraud cases, and that preservation will likely be felt most acutely in negotiations over settlement value, motion practice over remedies, and board-level decisions about whether to litigate or resolve an investigation. For companies and individuals facing SEC scrutiny, the economic stakes of enforcement remain as real as ever.

In a short but noteworthy unanimous decision issued on May 28, 2026, the Supreme Court affirmed the judgment below in No. 24-935, with Justice Gorsuch writing for the Court. Although the Court’s disposition is formally simple—“AFFIRMED”—the opinion matters because unanimous Supreme Court affirmances often clarify how lower courts and litigants should understand the boundaries of appellate review, statutory interpretation, or the proper framework for resolving recurring procedural disputes.

Based on the Court’s action, the key takeaway for practitioners is straightforward: the Supreme Court found no reversible error in the lower court’s reasoning or result, and the opinion now carries precedential weight because it was issued as a signed opinion of the Court rather than as an unexplained summary disposition. That means lawyers should pay close attention not only to the outcome, but also to the reasoning Justice Gorsuch used to explain why affirmance was required.

At a high level, an affirmance like this typically signals that the Court agreed with the governing legal rule applied below, rejected the petitioner’s effort to broaden or alter that rule, or concluded that the asserted error did not justify disturbing the judgment. If the dispute involved interpretation of a federal statute, regulation, or constitutional provision, the Court’s unanimous endorsement likely strengthens the lower court’s analytical framework and gives litigants a more stable roadmap going forward.

For appellate lawyers, the practical significance is twofold. First, unanimity narrows room for future arguments that the issue remains unsettled. Even where the opinion is narrow, a 9-0 ruling sends a strong message to lower courts about the proper approach. Second, affirmances often underscore preservation and framing: if a party’s theory was too ambitious, poorly tethered to text, or inconsistent with the record and procedural posture, the Court’s reasoning will likely be cited as a cautionary example in future briefing.

Practitioners should also consider how this opinion may affect case selection and cert strategy. A unanimous affirmance can indicate that the Court saw the issue as one of application rather than doctrinal innovation. That, in turn, may make it harder for future petitioners to argue that a circuit split or major legal uncertainty persists—unless they can identify materially different facts or a genuinely unresolved question left open by the opinion.

In short, while this decision does not appear to announce a dramatic doctrinal shift on its face, it likely consolidates existing law and gives lower courts firmer guidance on how to handle similar disputes. For litigators tracking the Court’s signals, that kind of clarification can be just as important as a reversal.

View full case on Docket Alarm

Antitrust enforcement remained one of the most important U.S. legal developments in the last 24 to 72 hours, with fresh activity in the government’s ongoing campaign against major technology platforms. Recent filings and hearing activity in several headline matters show enforcers moving beyond liability theories and deeper into the remedies phase—where structural relief, business-practice restrictions, and long-term compliance obligations become concrete risks rather than abstract possibilities.

That shift matters. For legal departments, the antitrust story is no longer just about whether the government can prove market power or exclusionary conduct. It is increasingly about what courts may be willing to do after a liability finding or a favorable appellate ruling: unwind acquisitions, impose interoperability or data-sharing obligations, restrict default arrangements, or require detailed reporting and monitoring regimes. Those are business-model questions as much as legal ones.

For litigators, the immediate takeaway is procedural as well as substantive. The current wave of antitrust cases shows how quickly post-trial and post-liability phases can reshape leverage. Remedy briefing, evidentiary disputes, expert submissions, and stay requests now carry outsized significance. Companies facing parallel scrutiny from the DOJ, FTC, and state attorneys general should expect plaintiffs to use momentum from one case to influence another, even when the legal theories differ.

In-house counsel and compliance teams should also treat the latest developments as a warning that ordinary commercial arrangements—exclusive defaults, self-preferencing allegations, bundled service design, data access restrictions, and partner incentive programs—can become central exhibits in monopolization litigation. That is especially true where internal business justifications are thin, inconsistent, or poorly documented. As regulators continue to test aggressive theories, contemporaneous records explaining product design, contracting choices, and competitive effects may become critical.

The broader significance is that federal antitrust enforcement is still operating at a high temperature despite leadership changes and political uncertainty. Courts are being asked not only to evaluate traditional Sherman Act claims, but also to define the boundaries of permissible platform governance in digital markets. Even where the government does not win every theory, the cost of defending these cases—and the operational consequences of partial losses—are substantial.

For legal professionals tracking exposure, the practical lesson is to watch the docket, not just the headlines. The most consequential developments often appear in scheduling orders, remedy proposals, expert challenges, and sealed or partially sealed submissions that signal where the court is focusing next. In the current environment, antitrust risk is increasingly shaped by litigation posture and judicial management as much as by headline legal doctrine.

A federal judge in the Eastern District of California has blocked Nexstar Media Group’s proposed acquisition of Tegna while antitrust litigation proceeds, handing opponents of the deal an important early win and underscoring how merger challenges can survive even after federal regulators decline to stop a transaction.

Judge Troy Nunley found that the challengers were likely to succeed, a significant conclusion at the preliminary injunction stage. The suit was brought by DirecTV and a coalition of eight state attorneys general, who argue the transaction would lessen competition in local television broadcasting and increase leverage over pay-TV distributors and consumers. The district court proceedings are consolidated in In Re: Nexstar-TEGNA Merger Litigation.

The ruling matters because it highlights a growing feature of modern antitrust enforcement: federal clearance is not always the end of the story. State AGs and private plaintiffs are increasingly willing to press independent theories of competitive harm, particularly in concentrated industries where pricing power, retransmission consent fees, and local market overlap can create pressure points. For dealmakers, that means merger risk analysis must extend beyond the FTC and DOJ to include parallel exposure from states, competitors, and major commercial counterparties.

It also offers a reminder that courts remain willing to pause transactions when plaintiffs can show likely antitrust injury before closing. That can alter negotiating leverage, financing assumptions, outside dates, and integration planning. For in-house counsel and compliance teams, the decision reinforces the importance of building a litigation-ready record around efficiencies, market definition, and consumer impact well before a merger challenge is filed.

The dispute is already moving on appeal. The related Ninth Circuit matter, DirecTV, LLC, et al. v. Nexstar Media Group, Inc., et al., will be worth close attention for practitioners tracking the appellate treatment of preliminary merger injunctions and the role of non-federal enforcers in antitrust cases.

For litigators, the case is a useful study in how private and state plaintiffs can frame a merger challenge around downstream pricing and bargaining dynamics rather than only traditional head-to-head overlap. For transactional lawyers, it is another signal that antitrust diligence must account for a broader set of challengers. And for media companies negotiating distribution rights, the decision may shape future assumptions about consolidation, leverage, and the limits of regulatory clearance as a shield against litigation.

The SEC is pushing back after a federal judge raised concerns about its proposed settlement with Elon Musk, with the agency arguing the deal is lawful, appropriate, and consistent with its enforcement discretion. The dispute puts a spotlight on a recurring question in securities enforcement: how much scrutiny should courts apply when regulators negotiate resolutions with high-profile defendants?

At issue is the SEC’s effort to defend a settlement arrangement after the judge reportedly cited “red flags” in reviewing the proposal. While courts often approve consent judgments in agency enforcement actions, this episode underscores that judicial review is not always perfunctory—especially when a case involves a prominent public figure, prior compliance issues, or questions about whether the agreed relief adequately protects investors.

For legal professionals, the significance goes beyond the personalities involved. For securities litigators, the matter is a reminder that settlements with federal regulators can still face meaningful judicial resistance, even when both sides want closure. Negotiated outcomes may need a more robust record on remedies, deterrence, and public interest than parties sometimes expect.

For in-house counsel and compliance teams, the case highlights the continuing governance risks that arise when executive conduct intersects with securities disclosure obligations and regulatory supervision. If a judge signals concern about the sufficiency or structure of an SEC deal, boards and compliance officers should take note: regulators may not be the only audience that matters. Courts may demand clearer explanations for why a resolution addresses repeat-risk, monitoring, or future compliance safeguards.

The matter also fits into a broader trend of judges taking a harder look at agency settlements, particularly in cases with reputational stakes or perceived enforcement asymmetries. That can affect settlement timing, negotiation leverage, and the drafting of injunctive terms, penalties, and undertakings. Companies resolving SEC investigations may want to assume that the court record could matter more than in years past.

Practically, this development may encourage both the SEC and defense counsel to build more detailed justifications into settlement papers—explaining not only what the parties agreed to, but why the result is fair, enforceable, and sufficient to deter future misconduct. In high-visibility matters, that extra groundwork may be the difference between a quick approval and a judge ordering further explanation or revisions.

For the securities bar, the takeaway is clear: settlement strategy is no longer just about reaching terms with the agency. It is also about anticipating judicial skepticism and framing the resolution in a way that can withstand public-interest review.

The Justice Department’s latest announcement around health care fraud enforcement is one of the more consequential legal developments for companies operating in regulated industries this week. According to the reporting referenced, federal authorities have highlighted a major enforcement push targeting fraud schemes tied to health care billing and reimbursement, underscoring that prosecutors continue to view the sector as a core enforcement priority.

For legal professionals, the story is not simply about another round of criminal charges. It signals the continued alignment of DOJ prosecutors, law enforcement agencies, and regulators around data-driven fraud detection, cross-agency coordination, and aggressive pursuit of individuals as well as corporate actors. That matters because health care fraud cases rarely stay confined to criminal exposure. They often trigger parallel civil False Claims Act risk, administrative exclusion proceedings, repayment demands, and follow-on private litigation.

The practical takeaway for in-house counsel and compliance teams is that billing integrity, referral relationships, documentation practices, and vendor oversight remain high-risk areas. Even where alleged misconduct begins with a narrow reimbursement issue, investigators often expand outward into theories involving kickbacks, medical necessity, telehealth arrangements, prescribing practices, or inadequate supervision. Once the government opens that door, companies can quickly face subpoenas, civil investigative demands, and difficult disclosure questions.

For litigators, the development is a reminder that enforcement trends shape the private docket as well as the public one. Criminal investigations can seed shareholder suits, employment disputes involving whistleblowers, and indemnification fights among corporate officers and service providers. Defense strategy also becomes more complex where companies must manage privilege, internal investigations, and cooperation decisions while anticipating collateral proceedings.

This renewed focus is especially important in an environment where DOJ has repeatedly emphasized deterrence through individual accountability and corporate compliance expectations. Prosecutors increasingly expect organizations to show they had workable controls in place before misconduct surfaced, not merely a remediation plan after investigators arrive. That raises the stakes for board reporting, audit trails, hotline intake, and escalation procedures.

More broadly, the announcement reflects a familiar but important enforcement reality: health care remains one of the most litigation-exposed sectors in the country. Providers, private equity-backed platforms, pharmacies, laboratories, telemedicine companies, and revenue-cycle vendors all sit within the government’s line of sight. Legal teams advising those clients should expect continued scrutiny of payment practices and be prepared for enforcement theories that blend criminal, civil, and regulatory tools.

In short, this is not just a headline about fraud arrests. It is another clear signal that DOJ is continuing to invest in health care enforcement infrastructure, and that companies in the space should treat compliance failures as enterprise-level litigation risks, not isolated reimbursement disputes.

Vivint LLC has filed a new petition for inter partes review at the Patent Trial and Appeal Board in IPR2026-00375, opened on June 1, 2026. At this early stage, the docket reflects the filing of the proceeding but does not yet publicly provide the full set of petition details needed to identify the challenged patent claims, the patent owner, or the precise prior-art combinations asserted. Even so, the filing is notable for practitioners who track PTAB activity in the home-security and connected-device space.

An IPR petition asks the Board to reconsider the validity of issued patent claims based on prior art consisting of patents or printed publications, typically under anticipation and obviousness theories under 35 U.S.C. §§ 102 and 103. Because this case has just been filed, counsel will want to watch for the petition, mandatory notices, and subsequent institution-related filings to see exactly which patent is being challenged, what claim construction positions are being advanced, and whether Vivint is pressing a single-reference anticipation theory, a multi-reference obviousness theory, or both.

The caption identifies Vivint LLC as the petitioner. The corresponding patent owner should become clearer as the docket develops and preliminary filings are posted. For in-house IP teams and outside counsel, that distinction matters: the identity of the patent owner often frames the broader business context, including whether the dispute stems from parallel district court litigation, licensing negotiations, or a larger campaign involving smart-home, monitoring, control-panel, sensor, or networked security technologies.

Why follow this proceeding now, before institution? First, newly filed IPRs often reveal a party’s broader invalidity and litigation strategy before those themes fully emerge in parallel cases. Second, PTAB petitions in the smart-home sector can offer useful insight into how challengers are attacking software-implemented and communications-related claims, especially where references concern remote monitoring, device pairing, event detection, automation workflows, or user-notification features. Third, timing matters: the institution briefing may preview estoppel risks, discretionary-denial arguments, and how the parties are positioning around parallel litigation schedules.

Patent practitioners should also watch for whether this filing becomes part of a coordinated series of challenges, whether discretionary denial under Fintiv-style considerations is raised, and how the Board approaches any real-party-in-interest or joinder issues. Those procedural developments can be just as significant as the merits for clients facing fast-moving infringement disputes.

For updates as the record develops, including the petition and later PTAB filings, View full case on Docket Alarm.

The Oklahoma Supreme Court has invalidated a closely watched settlement between the City of Tulsa and the Muscogee (Creek) Nation that sought to define how criminal cases involving Native Americans would be handled within reservation boundaries. In State of Oklahoma ex rel. Stitt v. City of Tulsa, the court concluded the agreement was not enforceable under Oklahoma law because it lacked approval from the governor and the legislature.

The ruling is significant because the settlement had attempted to create a practical framework for Tulsa’s continued exercise of criminal jurisdiction in an area where tribal, municipal, and state authority have been heavily contested since McGirt reshaped the legal map in eastern Oklahoma. By holding that the city could not enter this kind of arrangement on its own, the court reinforced the idea that jurisdictional compromises with sovereign implications must go through formal state-level channels.

For litigators, the decision matters well beyond Tulsa. It raises immediate questions about pending and future prosecutions involving Native American defendants, the validity of local enforcement practices adopted in reliance on intergovernmental agreements, and the procedural route required for any future tribal-state or tribal-municipal jurisdictional compact. Parties following the dispute can track the state high-court matter in Stitt vs City of Tulsa et al.

For in-house counsel and compliance teams, especially those advising municipalities, tribal entities, healthcare systems, casinos, and employers operating in eastern Oklahoma, the decision is a reminder that jurisdiction is not just a criminal-law issue. Questions about sovereignty and governmental authority can affect investigations, law-enforcement coordination, contracting, licensing, and risk assessments. Agreements that appear operationally sensible may still be vulnerable if statutory approval requirements are not satisfied.

The decision also adds another layer to an already active appellate landscape. The jurisdictional fight has generated proceedings in multiple courts, including a petition at the U.S. Supreme Court, Marvin Keith Stitt, Petitioner v. City of Tulsa, Oklahoma. That makes this more than a local governance dispute: it is part of a broader test of how Oklahoma, its cities, and tribal governments can structure criminal enforcement after McGirt.

The bottom line is clear. The Oklahoma Supreme Court did not simply reject one settlement; it signaled that major jurisdictional realignment cannot be accomplished through a city-tribe agreement alone. Any durable solution will likely require explicit political and statutory buy-in at the state level.

Seagate Technology has agreed to pay $175 million to resolve shareholder claims alleging the company misled investors about hard-drive sales to Huawei and its exposure under U.S. export-control laws. The proposed settlement, filed in federal court in San Francisco, ranks among the more significant recent securities resolutions tied to sanctions and export-control compliance issues.

The shareholder case centered on allegations that Seagate, along with CEO Dave Mosley and CFO Gianluca Romano, concealed or downplayed legal and regulatory risks arising from continued sales to Huawei after U.S. restrictions tightened. Investors claimed those alleged omissions inflated Seagate’s stock price and that the truth emerged only after regulatory scrutiny and penalties brought the company’s conduct into sharper focus.

For legal professionals, the settlement is notable not just for its size, but for what it says about the expanding overlap between trade compliance and securities litigation. Export-control issues once viewed primarily as regulatory or criminal-enforcement matters are increasingly becoming fodder for Rule 10b-5 class actions. When a company’s revenue depends in part on sales into politically sensitive markets, disclosure decisions about licensing, customer restrictions, and enforcement risk can quickly become securities-fraud flashpoints.

That dynamic should resonate with in-house counsel and compliance teams. Statements in earnings calls, risk factors, MD&A sections, and internal compliance reporting may all be scrutinized later through a securities-litigation lens. A case like this underscores the importance of aligning export-control assessments with public-company disclosure controls, particularly when the company is navigating a fast-changing sanctions or export regime.

For litigators, the settlement also reinforces how plaintiffs’ firms are framing these cases: not merely as failures to comply with trade laws, but as failures to accurately communicate known compliance risk to the market. That distinction matters. It can broaden the potential fallout from an export-control problem well beyond agency investigations and civil penalties, exposing issuers and executives to parallel shareholder claims and significant settlement pressure.

More broadly, Seagate’s resolution is another reminder that geopolitics now sits squarely inside securities risk analysis. Companies with exposure to restricted counterparties, China-related supply chains, or sensitive technologies should expect continued scrutiny from regulators, investors, and the plaintiffs’ bar alike. For defense counsel and legal departments, the practical lesson is clear: export-control compliance cannot be siloed. It must be integrated into disclosure governance, board-level oversight, and litigation readiness.

If approved, the settlement will close a closely watched chapter for Seagate, but it is unlikely to be the last case testing how federal securities law responds to alleged misstatements about sanctions and export-control exposure.

The Patent Trial and Appeal Board granted institution in IPR2026-00189, finding that the petitioner made the required threshold showing that at least one challenged claim is reasonably likely to be unpatentable. At the institution stage, that is the key question under 35 U.S.C. § 314(a): not whether the patent is ultimately invalid, but whether the petition presents a sufficiently strong merits case to justify full trial before the Board.

Although an institution decision is preliminary, it is often the first meaningful read on how the PTAB views the parties’ invalidity theories, prior art combinations, and claim construction disputes. Here, the Board’s grant indicates that the petition was not merely facially adequate; it persuaded the panel that the asserted grounds—typically anticipation and/or obviousness based on printed publications and expert support—warrant a full inter partes review.

For practitioners, the most important takeaway is procedural as much as substantive. PTAB panels continue to scrutinize whether a petition ties each claim limitation to the prior art with precision and whether any rationale for combining references is supported by record evidence rather than attorney argument alone. A granted institution generally means the petitioner successfully connected those dots. On the patent owner side, this underscores the importance of using the preliminary response strategically: arguments aimed at evidentiary gaps, weak motivation-to-combine theories, and claim construction can still defeat institution, but only where they materially undercut the petitioner’s likelihood of success.

The decision also matters because institution orders shape the remainder of the case. Once review is instituted, the proceeding moves into the trial phase, where the patent owner must decide whether to file a full response, submit expert testimony, pursue amendment, or coordinate PTAB strategy with parallel district court litigation or ITC proceedings. Even though the Board’s institution analysis is not a final merits determination, parties and co-pending courts frequently treat it as a practical signal about the strength of the challenged patent claims.

This decision does not, by itself, appear to announce a new rule of law or change PTAB precedent. Instead, it reflects continued application of the post-SAS institution framework: if at least one challenge satisfies the statutory threshold, the Board institutes review on the petition as presented. That makes the ruling significant less for doctrinal novelty than for what it shows about current PTAB expectations for a well-supported petition.

For patent litigators, the broader lesson is familiar but important: institution is won or lost in the petition record. Detailed claim charts, credible expert analysis, and a coherent obviousness narrative remain essential. View full case on Docket Alarm

The U.S. Supreme Court has unanimously rejected Mexico’s effort to hold American gun manufacturers liable for cartel violence, shutting down a closely watched suit that sought roughly $10 billion in damages. The decision is a significant win for the firearms industry and a forceful reaffirmation of the Protection of Lawful Commerce in Arms Act, or PLCAA, the federal statute that broadly shields gunmakers and sellers from many civil claims arising from criminal misuse of their products.

Mexico had argued that U.S. manufacturers and distributors knowingly facilitated illegal trafficking by designing, marketing, and distributing firearms in ways that predictably supplied cartel networks. The Court, however, concluded that those theories could not overcome PLCAA’s protections on the allegations presented. In practical terms, the ruling narrows the path for plaintiffs seeking to recast downstream criminal conduct as actionable misconduct by lawful manufacturers upstream.

For litigators, the opinion is an important pleading-stage decision. It signals that courts are likely to scrutinize efforts to fit firearms claims within PLCAA exceptions, including theories tied to alleged statutory violations or aiding-and-abetting style conduct. Plaintiffs will need more than broad allegations about foreseeability, market conditions, or generalized knowledge of trafficking risks. Defense counsel, meanwhile, will view the ruling as strong authority for early dismissal in suits attempting to impose liability for third-party crimes.

The decision also matters well beyond the firearms space. In-house counsel and compliance teams should read it as part of a broader judicial trend limiting attempts to extend product-liability and public-nuisance theories across long causal chains involving criminal actors. Where a federal immunity statute applies, the Court appears unwilling to allow creative pleading to erode that protection absent clear, well-supported allegations that fit a statutory exception.

For companies operating in regulated industries, the case is a reminder that compliance records, distribution controls, dealer oversight, and marketing practices still matter. Even when immunity defenses are available, plaintiffs and regulators will continue testing the boundaries through allegations focused on sales channels, red-flag customers, and internal knowledge. A robust compliance framework remains the best first line of defense.

Cross-border litigation strategy is another takeaway. Mexico’s suit was closely watched because it attempted to use U.S. courts to address harms occurring largely outside the United States. The Supreme Court’s ruling makes clear that, at least in the PLCAA context, foreign sovereign plaintiffs face the same statutory barriers as private claimants. That has implications for future transnational suits seeking to connect domestic commercial conduct with violence, trafficking, or public harms abroad.

Expect this decision to be cited quickly in firearms cases nationwide, particularly where plaintiffs seek to proceed under novel negligence, nuisance, or statutory-violation theories despite PLCAA’s broad shield.

The SEC’s reported move to withdraw a judgment against the Winklevoss-linked crypto exchange Gemini marks one of the more consequential digital-asset enforcement developments now circulating in the legal market. Even without a fully public merits ruling to dissect, the significance is clear: a federal securities regulator appears to be stepping back from a previously obtained result in a high-profile crypto matter, underscoring how quickly the enforcement landscape can shift as policy priorities, litigation risk, and legal theories evolve.

For legal professionals, the immediate takeaway is not simply that one company may get relief. It is that the government’s posture in crypto cases remains fluid, particularly where courts, agencies, and market participants are still testing the boundary between securities regulation and newer digital-asset products. A withdrawn or vacated judgment can reshape leverage in parallel matters, alter settlement expectations, and embolden defendants facing similar allegations involving exchange operations, yield products, or token-related services.

For litigators, this development is a reminder to revisit assumptions baked into pending enforcement defenses. Arguments that once seemed uphill—such as challenges to the fit between legacy securities doctrines and crypto platforms—may gain renewed traction when the SEC itself reassesses a litigated outcome. Defense counsel will also be watching for procedural details: whether the withdrawal stems from a negotiated resolution, a strategic agency recalibration, or concerns about the sustainability of the judgment on appeal or in future proceedings.

In-house counsel and compliance teams should be cautious about reading this as broad deregulation. A retreat in one case does not eliminate securities, commodities, anti-fraud, AML, sanctions, or state-law exposure. Instead, it reinforces the need for risk assessments that are product-specific and regulator-specific. Firms in the digital-asset space should be reviewing offering structures, disclosures, custody arrangements, retail communications, and institutional lending or staking programs with an eye toward inconsistent enforcement signals across agencies.

The broader legal significance is institutional. When a major regulator moves to undo a judgment in a marquee crypto case, it affects not only the defendant but the credibility and predictability of enforcement doctrine. That matters for courts managing related cases, companies deciding whether to litigate or settle, and insurers and investors pricing legal risk. In the near term, practitioners should expect this development to be cited in negotiations, briefing, and boardroom discussions as a sign that crypto enforcement strategy remains very much in flux.